Ossianix

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders See more here

Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies A highly potent panel of VNARs against the SARS-CoV-2 spike protein has been isolated Neutralization of SARS-CoV-2 was demonstrated in in vitro infectivity assays In vitro blocking activities were also…

Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies - Over 30-Fold Increase in Hippocampus Observed - - Results Promising for Delivery of Biological Therapeutics for Neurologic Diseases - - Results to be Presented at Protein & Antibody Engineering Summit…

Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein. See more here

Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases See more here

Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology See more here

Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics Read More Here

Ossianix Announces Research Collaboration with Lundbeck Read more here

Ossianix Announces Lundbeck Investment Read more here